Humatrix

Humatrix was founded on September 1, 2021, in Suzhou Industrial Park. It is a leading tissue engineering and regenerative medicine technology platform company, initially focusing on the development and production of allogeneic small-diameter tissue-engineered blood vessels for applications such as establishing vascular access for chronic renal failure dialysis, peripheral arterial trauma replacement, peripheral arterial atherosclerosis, and coronary artery bypass grafting. Building on this technological platform, the company develops and produces allogeneic regenerative medicine products (such as tissue-engineered ureters, tissue-engineered heart valves, nerve repair conduits, acellular tissues and organs) and expands into global clinical research and commercialization to meet the growing and largely unmet clinical needs.